Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market Outlook - 2026
The global acute lymphocytic/lymphoblastic leukemia therapeutics market accounted for $2,334.5 million in 2018, and is expected to reach $3,528.8 million by 2026, registering a CAGR of 5.3% from 2019 to 2026.
Acute lymphocytic/lymphoblastic leukemia (ALL) is a type of cancer that develops from immature lymphocytes. “Acute” here indicates leukemia that quickly progresses and spreads across the body. ALL develops in bone marrow and quickly invades other parts of the body including the liver, spleen, lymph nodes, liver, central nervous system, spleen, central nervous system, and the blood. Symptoms can be non-specific and may include feeling weak and tired, paler skin, bruises, frequent and severe bleeding gums, nose bleeds; weight loss, shortness of breath, and loss of appetite. Various types of therapeutics are used for ALL treatment. Chemotherapy is one of the major therapeutics used for ALL treatment.
The market is experiencing growth owing to rise in incidences of acute lymphoblastic leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D of different leukemia and rise in awareness of targeted therapies amongst the population further drive the growth of the ALL therapeutics market. Despite these, the stringent regulatory approvals for the therapeutics and the adverse side effects of the drugs used in the therapy impede the growth of the market worldwide. Also, patent expiry of the blockbuster drugs used in the treatment and the higher costs involved in the therapies limit the growth of the global ALL therapeutics market. Nonetheless, the rise in number of clinical trials and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets.
Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market Segmentation
The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on drug, type, and region to provide a detailed assessment of the market. Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. Based on type, it is classified into pediatrics and adults. Based on region, the acute lymphocytic/lymphoblastic leukemia therapeutics market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment review
Based on drug, the market is divided into Hyper-CVAD Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar and Nelarabine), Targeted Drugs & Immunotherapy, CALGB 8811 Regimen, and Oncaspar. The Hyper-CVAD Regimen acquired the largest acute lymphocytic/lymphoblastic leukemia therapeutics market share in 2018 owing to wide usage in the ALL treatment. Hyper-CVAD Regimen is considered as one of the most commonly used therapy options for acute lymphocytic/lymphoblastic leukemia.
Furthermore, targeted drugs & immunotherapy are projected to grow at the fastest rate during the forecast period as these drugs have shown potential in the treatment of relapsed acute lymphocytic leukemia and is widely used in patients who do not respond to chemotherapy. Therefore, these factors contribute toward the growth of the ALL therapeutics market.
According to type, the pediatrics segment generated the highest revenue in 2018 and is expected to maintain its dominance throughout the forecast period. This is attributed to the high incidences of acute lymphocytic/lymphoblastic leukemia among pediatric population. Acute lymphocytic/lymphoblastic leukemia is considered as one of the most common cancer types in pediatric population. Moreover, pediatric population have higher success rate for acute lymphocytic/lymphoblastic leukemia treatments.
North America occupied the largest share of the market in 2018 and is expected to maintain its dominance during the forecast period owing to easy availability of treatments, high cost of treatments, and presence of majority of key players. However, Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base and rise in patient awareness toward cancer care.
The major companies profiled in this report include Amgen, Inc., Bristol-Myers Squibb Company, Erytech Pharma, Leadiant Biosciences, Inc. (Sigma-Tau Pharmaceuticals Inc.), Novartis AG, Pfizer, Inc., Rare Disease Therapeutics, Inc., Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
Key Market Benefits for Acute Lymphocytic/lymphoblastic Leukemia Therapeutics Market:
- This report entails a detailed quantitative analysis along with the current acute lymphocytic/lymphoblastic leukemia therapeutics market trends from 2018 to 2026 to identify the prevailing opportunities along with the strategic assessment of the global acute lymphocytic/lymphoblastic leukemia therapeutics market growth.
- The market forecast is studied from 2019 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the acute lymphocytic/lymphoblastic leukemia therapeutics industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Acute Lymphocytic-Lymphoblastic Leukemia (ALL) Therapeutics Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Drug |
|
 By Region |
|
 Key Market Players | LEADIANT BIOSCIENCES, INC. (SIGMA-TAU PHARMACEUTICALS INC.), AMGEN, INC, TAKEDA PHARMACEUTICAL COMPANY LIMITED, SPECTRUM PHARMACEUTICALS, INC, NOVARTIS AG, ERYTECH PHARMA, PFIZER, INC, BRISTOL-MYERS SQUIBB COMPANY, SANOFI, RARE DISEASE THERAPEUTICS, INC. |
Analyst Review
Acute lymphocytic/lymphoblastic leukemia therapeutics (ALL) is one of the most common acute leukemia in children and adults. Newer lab techniques and targeted therapy drugs against ALL are now being developed. The targeted therapy drugs are now becoming an important part in the ALL therapeutics market as they work differently from standard chemotherapy drugs by targeting specific gene inside normal bone marrow cells. Asia-Pacific is projected to register highest growth rate in the global acute lymphocytic/lymphoblastic leukemia therapeutics market due to massive increase in population, high prevalence of lymphoblastic leukemia, and rise in the healthcare market.
Rise in incidence rates and increase in prevalence rates of lymphoblastic leukemia, implementation of national screening programs, and support in reimbursement for ALL therapeutics are the major factors that drive the growth of the market. However, high costs associated with the treatment for cancer refrain patients from diagnosis and treatment. Moreover, side effects of the drugs used in the therapies significantly limits the diagnosis of lymphoblastic leukemia. Such factors are expected to restrain the market growth.
Loading Table Of Content...
